Healthcare

For most of its listed life, Dimerix (ASX: DXB) has been a one-drug story, with investors watching every twist in the pivotal Phase 3 trial of its kidney candidate DMX-200. That narrative widened sharply in July 2026. On 17 July the company announced it …

Cochlear (ASX: COH), the Sydney-based world leader in implantable hearing devices, has spent much of the past 18 months navigating a shifting United States trade landscape. On 24 July 2026 the company told the market that its hearing implant systems would continue to enter …

Few sectors carry more emotional weight, or more commercial promise, than the search for a workable treatment for Alzheimer's disease. So when Ceretas (ASX:CTS) rang the bell on the Australian Securities Exchange on 23 July 2026, having raised roughly $8 million in its initial …

The Brisbane-based workforce group listed in 2017 as People Infrastructure and spent its first five years as an acquisitive roll-up of staffing agencies. Its shares last changed hands at 71.5 cents on ASX data, within a 52-week range of 52.5 to 95 cents, valuing …

None of that, alone, turns a company that has never sold a registered product into a commercial one. What ties the three together is sequencing: Recce is betting an Indonesian approval can be leveraged into Middle Eastern registrations without repeating the clinical work, while …

The company is a clinical-stage medical technology business built around one idea: that carefully targeted sound waves, delivered through a wearable device rather than through surgery, can influence brain tissue in people with Alzheimer's disease. The science came out of the Queensland Brain Institute …

The response was emphatic rather than muted. StockLight's record of the company's announcements puts the share price impact of the 22 July release at roughly 32 per cent, and the May update at about 18 per cent. Shares last traded at 43 cents, down …